Find a Trial

Trial Results


8 protocol(s) meet the specified criteria
ADVL1514OPEN TO ACCRUAL
A PHASE 1 STUDY OF ABI-009 (NAB-RAPAMYCIN) IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN
PHO-COG-AREN1921OPEN TO ACCRUAL
AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-COG-PEPN1812OPEN TO ACCRUAL
A PHASE 1 TRIAL OF THE CD123 X CD3 DUAL AFFINITY RE-TARGETING ANTIBODY FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
PHO-COG-PEPN1924OPEN TO ACCRUAL
PEPN1924, A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma.
PHO-EISAI-E7080-G000-230OPEN TO ACCRUAL
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
PHO-LILLY-JV01-ADVL2021AOPEN TO ACCRUAL
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients andYoung Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
PHO-LILLY-JV02-ADVL2021BOPEN TO ACCRUAL
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma